EF Hutton Maintains Buy Rating for Hoth Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
EF Hutton has maintained its Buy rating for Hoth Therapeutics (NASDAQ:HOTH) but lowered its price target from $12.00 to $7.50. Hoth Therapeutics' shares are currently trading down 11.41% at $1.70 per share. A move to $7.50 would represent a 340.92% increase from the current share price.
September 14, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
EF Hutton has maintained its Buy rating for Hoth Therapeutics but lowered its price target. This could potentially lead to increased volatility in the short term.
The decision by EF Hutton to maintain its Buy rating but lower the price target for Hoth Therapeutics could lead to increased volatility in the stock's price. Investors may interpret this as a mixed signal, which could lead to uncertainty and increased trading activity.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100